Company
Bonum Therapeutics
Antibody Controlled Therapeutics
Also known as BONUM THERAPEUTICS, INC.
- Status
- Operatingas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- Seattle, WA, United States
- Employees
- 31-person teamSource (opens in a new tab)
- Legal name
- BONUM THERAPEUTICS, INC.
Claim, correct or request removal
Record updated 28 September 2026
About
Bonum Therapeutics uses a novel, antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines - two programs created with this platform are in preclinical development.
Funding snapshot
- Total raised
- $73.1MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $26.9M2026-04-03
Funding rounds
- Round, 2026
- $26.9M2026-04-03, SEC form D sold, 8 investors
- Round, 2022
- $45M2022-11-15, SEC form D sold, 10 investors
- Round, 2021
- $1.2M2021-12-08, SEC form D sold, 5 investors
Loading relationship preview